

# Ma Ai Thanda Han

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3707590/publications.pdf>

Version: 2024-02-01

17  
papers

461  
citations

1162889

8  
h-index

1199470

12  
g-index

17  
all docs

17  
docs citations

17  
times ranked

807  
citing authors

#	ARTICLE	IF	CITATIONS
1	Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial. <i>Lancet Infectious Diseases</i> , The, 2015, 15, 1167-1174.	4.6	216
2	Rates of and Factors Associated With Placebo Response in Trials of Pharmacotherapies for Nonalcoholic Steatohepatitis: Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 616-629.e26.	2.4	91
3	MR elastography-based liver fibrosis correlates with liver events in nonalcoholic fatty liver patients: A multicenter study. <i>Liver International</i> , 2020, 40, 2242-2251.	1.9	48
4	Magnetic resonance imaging and transient elastography in the management of Nonalcoholic Fatty Liver Disease (NAFLD). <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 379-390.	1.3	30
5	Magnetic Resonance Elastography Shear Wave Velocity Correlates with Liver Fibrosis and Hepatic Venous Pressure Gradient in Adults with Advanced Liver Disease. <i>BioMed Research International</i> , 2017, 2017, 1-8.	0.9	29
6	The balance of type 1 and type 2 immune responses in the contexts of hepatitis B infection and hepatitis D infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 764-775.	1.4	15
7	Noninvasive Tests (NITs) for Hepatic Fibrosis in Fatty Liver Syndrome. <i>Life</i> , 2020, 10, 198.	1.1	11
8	Pharmacokinetics and pharmacodynamics modeling of lonafarnib in patients with chronic hepatitis delta virus infection. <i>Hepatology Communications</i> , 2017, 1, 288-292.	2.0	10
9	A randomized, proof-of-concept clinical trial on repurposing chlorcyclizine for the treatment of chronic hepatitis C. <i>Antiviral Research</i> , 2019, 163, 149-155.	1.9	6
10	Fibrosis Changes in the Placebo Arm of NASH Clinical Trials. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2387.	2.4	3
11	The emperor's new clothes: hypersensitivity of the new cardiac isoenzymes. <i>Journal of Community Hospital Internal Medicine Perspectives</i> , 2013, 3, 20354.	0.4	1
12	Pharmacokinetics and pharmacodynamics modeling of ritonavir boosted lonafarnib therapy in HDV patients: A phase 2 LOWR HDV-3 study. <i>Journal of Hepatology</i> , 2018, 68, S508.	1.8	1
13	LP36 : Understanding hepatitis delta virus and HBsAG kinetics during treatment with prenylation inhibitor lonafarnib via mathematical modeling. <i>Journal of Hepatology</i> , 2015, 62, S281-S282.	1.8	0
14	Pharmacokinetics and Pharmacodynamics Modeling of Lonafarnib in Patients with Chronic Hepatitis Delta Virus Infection. <i>Journal of Hepatology</i> , 2016, 64, S589.	1.8	0
15	Tu1725 Deficiency of Adenosine Deaminase 2 (DADA2): A Rare Cause of Hepatoportal Sclerosis and Non-Cirrhotic Portal Hypertension. <i>Gastroenterology</i> , 2016, 150, S1172-S1173.	0.6	0
16	Hepatobiliary and Pancreatic: Not all that "Glisson's" is fat. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 1515-1515.	1.4	0
17	THU-311-Liver enzymes cut offs in patients with advanced non-alcoholic fatty liver disease: A multi-center study. <i>Journal of Hepatology</i> , 2019, 70, e297.	1.8	0